Investigating Neurobiology and New Treatments for Addiction, Depression and Anxiety
02 févr. 2022 11h05 HE
|
Brain & Behavior Research Foundation
New York, Feb. 02, 2022 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Investigating Neurobiology and New Treatments for Addiction, Depression...
CenExel Clinical Research Acquires California Neuroscience Research
10 janv. 2022 13h10 HE
|
CenExel Clinical Research
Salt Lake City, Utah, Jan. 10, 2022 (GLOBE NEWSWIRE) -- CenExel Clinical Research, Inc., (“CenExel”) announces the acquisition of California Neuroscience Research (“CenExel CNR”), a clinical...
Prenatal Exposures and Experiences: Impact on Children’s Early Brain Development and Risk for Disease
10 janv. 2022 08h00 HE
|
Brain & Behavior Research Foundation
New York, Jan. 10, 2022 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Prenatal Exposures and Experiences: Impact on Children’s Early Brain...
Nexstim Receives Order for Two NBT® Systems from Finnish University Hospital Customer
10 déc. 2021 02h00 HE
|
Nexstim Oyj
Press release, Helsinki, December 10, 2021 at 9 AM (EET) Nexstim Receives Order for Two NBT® Systems from Finnish University Hospital Customer Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or...
OCD: Using Genome Data to Predict Risk, Symptoms and Treatment Response - A Free Webinar from the Brain & Behavior Research Foundation
07 déc. 2021 09h00 HE
|
Brain & Behavior Research Foundation
New York, Dec. 07, 2021 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “OCD: Using Genome Data to Predict Risk, Symptoms and Treatment Response”...
OWP Pharmaceuticals Announces IND Authorization for the First-Ever Oral Liquid Formulation of Atomoxetine Hydrochloride for the Treatment of Attention Deficit Hyperactivity Disorder
17 nov. 2021 08h00 HE
|
OWP Pharmaceuticals, Inc.
NAPERVILLE, Ill., Nov. 17, 2021 (GLOBE NEWSWIRE) -- OWP Pharmaceuticals, Inc. is a privately held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and...
Nexstim aloittaa yhteistyön suomalaisen yksityisklinikan kanssa ja etenee strategisissa tavoitteissaan
05 nov. 2021 03h00 HE
|
Nexstim Oyj
Lehdistötiedote, Helsinki, 5.11.2021 klo 9.00 (EET) Nexstim aloittaa yhteistyön suomalaisen yksityisklinikan kanssa ja etenee strategisissa tavoitteissaan Nexstim Oyj (NXTMH:HEX, NXTMS:STO)...
Nexstim engages in cooperation with private Finnish clinic and makes progress in its strategic goals
05 nov. 2021 03h00 HE
|
Nexstim Oyj
Press release, Helsinki, 5 November 2021 at 9 AM (EET) Nexstim engages in cooperation with private Finnish clinic and makes progress in its strategic goals Nexstim Plc (NXTMH:HEX, NXTMS:STO)...
Developing New Treatments for Mania Using Brain-Based Risk Markers - A Free Webinar from the Brain & Behavior Research Foundation
04 nov. 2021 08h59 HE
|
Brain & Behavior Research Foundation
New York, Nov. 04, 2021 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Developing New Treatments for Mania Using Brain-Based Risk Markers” on...
Nexstim Releases the New NBS5+ in the United States
22 oct. 2021 02h00 HE
|
Nexstim Oyj
Press release, Helsinki, 22 October 2021 at 9 AM (EEST) Nexstim Releases the New NBS5+ in the United States Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces the launch of a new...